NCT00750399View on ClinicalTrials.gov

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Radiation RetinopathyChoroidal Melanoma
Interventions
DRUG

Ranibizumab

intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.

DRUG

ranibizumab

intravitreal ranibizumab 0.5 mg

Trial Locations (1)

10065

The New York Eye Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

The New York Eye Cancer Center

OTHER